Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVIR
AVIR logo

AVIR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Atea Pharmaceuticals Inc (AVIR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
4.490
1 Day change
3.22%
52 Week Range
6.450
Analysis Updated At
2026/06/26
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

AVIR is not a good buy right now for a Beginner long-term investor with $50,000-$100,000. The stock is weakly positioned despite a few short-term bullish technical signals, and the lack of news, financial data, and catalyst support makes it unattractive for an immediate purchase. Given the user's impatience and desire not to wait for a better entry, the direct answer is to avoid buying now.

Technical Analysis

AVIR is trading at 4.345, slightly below the previous close of 4.35 and down 2.90% on the day. The chart setup is mixed: SMA_5 > SMA_20 > SMA_200 is bullish on trend structure, but RSI_6 at 44.16 is neutral and MACD histogram at 0.0427 is positive but contracting, suggesting momentum is fading. Price is below the pivot at 4.398 and close to support at 4.261, while resistance sits at 4.536 and 4.621. The short-term stock trend model is negative for 1 week and 1 month, which weakens the case for an immediate long-term entry.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on paper because both put-call ratios are very low, indicating call-heavy positioning. Call open interest is 1317 versus put open interest of 87, and daily option volume is also call-dominant at 10 calls vs 1 put. However, this bullish options tone is not backed by strong price momentum or a catalyst. Implied volatility is elevated at 143.42, suggesting traders are paying up for upside exposure, but this does not override the weak near-term price trend.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
10

Positive Catalysts

  • ["Bullish moving average alignment: SMA_5 > SMA_20 > SMA_200", "Options flow is heavily call-biased, indicating bullish sentiment", "MACD histogram remains above zero, so the trend is not fully broken"]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no event-driven catalyst", "Stock trend model points to -3.53% next week and -4.93% next month", "Price is below pivot, showing weak immediate momentum", "Hedge funds are neutral with no meaningful accumulation", "Insiders are neutral with no recent positive buying trend", "No recent congress trading data", "High implied volatility can reflect speculative positioning rather than durable demand"]

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so there is no reliable revenue, earnings, or growth trend to support a long-term buy decision. The latest quarter season cannot be confirmed from the available data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence of improving Wall Street consensus or rising targets. As a result, the Wall Street pros view cannot be described as constructive based on the available inputs.

Wall Street analysts forecast AVIR stock price to rise
2 Analyst Rating
Wall Street analysts forecast AVIR stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.350
sliders
Low
6
Averages
6
High
6
Current: 4.350
sliders
Low
6
Averages
6
High
6
Evercore ISI
NULL -> Outperform
upgrade
$6 -> $10
AI Analysis
2026-03-09
Reason
Evercore ISI
Price Target
$6 -> $10
AI Analysis
2026-03-09
upgrade
NULL -> Outperform
Reason
Evercore ISI raised the firm's price target on Atea Pharmaceuticals to $10 from $6 and keeps an Outperform rating on the shares.

People Also Watch